Hansa Biopharma — December 2021
-
Godt det går godt for en Hansa Biopharma-partner: "Under the terms of the agreement, Sarepta obtains an exclusive, worldwide license to develop and promote imlifidase as a pre-treatment to enable Sarepta gene therapy administration in Duchenne muscular dystrophy (DMD) and Limb-girdle muscular dystrophy (LGMD), for patients who may otherwise not be eligible for treatment."
-
Hansa Biophama giver nyt håb til nyre patienter og vi ser gode chancer for comeback i aktien https://kapitalpartner.dk/hansa-biophama-giver-nyt-haab-til-nyre-patienter-og-vi-ser-gode-chancer-for-comeback-i-aktien/
-
Fra euroinvestor Kapital Partner analytiker Frank Hørning Andersen ser stort potentiale i Hansa: https://www.euroinvestor.dk/nyheder/ser-stort-potentiale-i-glemt-biotek-aktie
-
Hansa Biopharma afholder Q&A torsdag d. 16 kl. 20-20,45. Tilmelding ved mail til [email protected]
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind